Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346302 · ClinicalTrials.gov registry record · Early Phase 1
Persistent Readiness Through Early Prediction Immunization Study
A Early Phase 1 study of Inflammatory Response, sponsored by Texas A&M University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 249
- Enrollment target
- 1
- Study location
NCT05346302: Completed Early Phase 1 study of Inflammatory Response, sponsored by Texas A&M University.
NCT05346302 is a Early Phase 1 study of Inflammatory Response that has completed, run by Texas A&M University. The registered enrollment target is 249 participants, above the 162-participant average among 16 other Inflammatory Response trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05346302, a Early Phase 1 study of Inflammatory Response, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 249 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll volunteers in an open-format (outside hospital) setting, to complete novel data collection/analysis of biomarkers, facial images, and audio-recording to establish an optimal set of parameters to predict emergent cases of infection via an early warning score, along with actionable personalized information.
Primary Outcome
Using a daily electronic questionnaire to collect data that self-reporting changes in general physical health and physiological measurements to identify the type of intervention
Conditions Studied
Interventions
- OTHER Saline
- DRUG Pneumovax 23
- DRUG Typhim VI
Study Locations (1)
Texas
- Texas A&M University - CTRAL - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2022-12-21 |
| Phase | Early Phase 1 |
What the finished NCT05346302 record still lists
NCT05346302 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, above the 162-participant average among 16 other Inflammatory Response trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Inflammatory Response appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT05346302 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05346302 about?
NCT05346302 is a clinical study titled "Persistent Readiness Through Early Prediction Immunization Study". This study will enroll volunteers in an open-format (outside hospital) setting, to complete novel data collection/analysis of biomarkers, facial images, and audio-recording to establish an optimal set of parameters to predict emergent cases of infection via an early warning score, along with actiona...
What is the current status of trial NCT05346302?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 249 participants. The study started on 2022-02-08. Estimated completion is 2022-12-21.
What conditions does trial NCT05346302 study?
This clinical trial studies the following conditions: Inflammatory Response.
What interventions are being tested in trial NCT05346302?
The interventions under investigation include: Saline (OTHER), Pneumovax 23 (DRUG), Typhim VI (DRUG).
Who is sponsoring clinical trial NCT05346302?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05346302 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Response
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05346302's enrollment target sits among peer trials
249 3rd of 16 higher than 14 of 16 other Inflammatory Response trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammatory Response trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep and Inflammatory Resolution Pathway
ACTIVE NOT RECRUITING · Early Phase 1
-
Menthol, Inflammation, and Nicotine Transition Study
RECRUITING · NA
-
Examining the Role of Female Endogenous Sex Hormones in Eccentric Exercise
RECRUITING · NA
-
Association Between Body Composition and Pain in Spinal Cord Injury
RECRUITING · NA
-
Social Experiences and Demographic Factors in the Regulation of Immune Cells
RECRUITING · NA
-
Daoist Zhanzhuang and Human Flourishing
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI